2025 Q4 -tulosraportti
UUTTA
1 päivä sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
0
Myynti
Määrä
4 650
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·22 t sittenAlways a positive headline on the quarterly reports, higher sales, higher ebitda etc. But if you know the company, you know what's coming. There's always something further down in the financial statements that ruins it and the money drains away. So this time too, they manage to lose over 11 million kroner on the bottom line. They never manage to be left with money; costs just increase proportionally.
·21 t sittenI disagree here. Positive cash flow in the quarter of 14m from operations which is quite on par with EBITDA, meaning that most comes from actual sales and not adjustment of working capital items. The loss on the bottom line comes from a larger write-down in the quarter, where parts come from Dne Pharma which is now consolidated into the figures, as well as I suspect that a further write-down of loans to Observe is included here. Lars Hjarrand has probably done a lot of good over the years, but in the last 2årene I think choices were made that made it seem like he wasn't as "on it". Very pleased that the new CFO shows new initiatives and takes action and shares a concrete plan to reduce the debt that has accumulated. That it will be a cleanup job and that there is enough to tackle, I would assume, but I think they show new momentum and I am positive.·14 t sittenSure, they had decent cashflow. But I think the report was weak, they are reducing earnings in the important consumer health area, sales of Mysimba (weight loss drug) are falling 20%(!) and they are losing over 11 mill kr before tax. This is how I feel almost every single report is, I've owned them for some years now. It has been a terrible investment.
·29.1.Norne Sec. reiterates target price NOK36 ahead of the Q4 report: Material revenue gains, albeit higher amortisation expectations in 4Q Navamedic’s 4Q figures are expected to reflect a more comprehensive contribution from the consolidation of dne. Solid underlying growth across all segments and continued strategic execution observed thus far reinforce our positive view on the stock. While higher amortisation of intangibles is likely to weigh on near-term reported earnings, we expect margins to benefit from the higher-margin dne portfolio and Flexilev. We reiterate our BUY recommendation and maintain our TP at NOK 36/sh., underpinned by confidence in the company’s long-term growth and value-creation potential. With offsetting developments, EPS is estimated to stay negative Navamedic will report 4Q results on February 12th. We estimate 4Q revenues at NOK 163.7m, implying an increase of ~25% YoY and ~18% QoQ. The topline is expected to reflect acquisition-driven growth gains in the quarter. We also expect the company to incur transaction-related costs of ~NOK 1.6m (vs NOK 2.3m in 3Q). For 4Q, we forecast adj. EBITDA of NOK 15.6m. Amortisation expenses are projected to increase in 4Q and remain elevated thereafter, driven by a larger intangible base following the dne acquisition, as well as the commencement of amortisation for parts of the Flexilev intangibles from 4Q25. We forecast EPS of NOK -0.10, or NOK -0.04 on an adjusted basis
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
1 päivä sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22 t sittenAlways a positive headline on the quarterly reports, higher sales, higher ebitda etc. But if you know the company, you know what's coming. There's always something further down in the financial statements that ruins it and the money drains away. So this time too, they manage to lose over 11 million kroner on the bottom line. They never manage to be left with money; costs just increase proportionally.·21 t sittenI disagree here. Positive cash flow in the quarter of 14m from operations which is quite on par with EBITDA, meaning that most comes from actual sales and not adjustment of working capital items. The loss on the bottom line comes from a larger write-down in the quarter, where parts come from Dne Pharma which is now consolidated into the figures, as well as I suspect that a further write-down of loans to Observe is included here. Lars Hjarrand has probably done a lot of good over the years, but in the last 2årene I think choices were made that made it seem like he wasn't as "on it". Very pleased that the new CFO shows new initiatives and takes action and shares a concrete plan to reduce the debt that has accumulated. That it will be a cleanup job and that there is enough to tackle, I would assume, but I think they show new momentum and I am positive.·14 t sittenSure, they had decent cashflow. But I think the report was weak, they are reducing earnings in the important consumer health area, sales of Mysimba (weight loss drug) are falling 20%(!) and they are losing over 11 mill kr before tax. This is how I feel almost every single report is, I've owned them for some years now. It has been a terrible investment.
- ·29.1.Norne Sec. reiterates target price NOK36 ahead of the Q4 report: Material revenue gains, albeit higher amortisation expectations in 4Q Navamedic’s 4Q figures are expected to reflect a more comprehensive contribution from the consolidation of dne. Solid underlying growth across all segments and continued strategic execution observed thus far reinforce our positive view on the stock. While higher amortisation of intangibles is likely to weigh on near-term reported earnings, we expect margins to benefit from the higher-margin dne portfolio and Flexilev. We reiterate our BUY recommendation and maintain our TP at NOK 36/sh., underpinned by confidence in the company’s long-term growth and value-creation potential. With offsetting developments, EPS is estimated to stay negative Navamedic will report 4Q results on February 12th. We estimate 4Q revenues at NOK 163.7m, implying an increase of ~25% YoY and ~18% QoQ. The topline is expected to reflect acquisition-driven growth gains in the quarter. We also expect the company to incur transaction-related costs of ~NOK 1.6m (vs NOK 2.3m in 3Q). For 4Q, we forecast adj. EBITDA of NOK 15.6m. Amortisation expenses are projected to increase in 4Q and remain elevated thereafter, driven by a larger intangible base following the dne acquisition, as well as the commencement of amortisation for parts of the Flexilev intangibles from 4Q25. We forecast EPS of NOK -0.10, or NOK -0.04 on an adjusted basis
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
0
Myynti
Määrä
4 650
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
2025 Q4 -tulosraportti
UUTTA
1 päivä sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22 t sittenAlways a positive headline on the quarterly reports, higher sales, higher ebitda etc. But if you know the company, you know what's coming. There's always something further down in the financial statements that ruins it and the money drains away. So this time too, they manage to lose over 11 million kroner on the bottom line. They never manage to be left with money; costs just increase proportionally.·21 t sittenI disagree here. Positive cash flow in the quarter of 14m from operations which is quite on par with EBITDA, meaning that most comes from actual sales and not adjustment of working capital items. The loss on the bottom line comes from a larger write-down in the quarter, where parts come from Dne Pharma which is now consolidated into the figures, as well as I suspect that a further write-down of loans to Observe is included here. Lars Hjarrand has probably done a lot of good over the years, but in the last 2årene I think choices were made that made it seem like he wasn't as "on it". Very pleased that the new CFO shows new initiatives and takes action and shares a concrete plan to reduce the debt that has accumulated. That it will be a cleanup job and that there is enough to tackle, I would assume, but I think they show new momentum and I am positive.·14 t sittenSure, they had decent cashflow. But I think the report was weak, they are reducing earnings in the important consumer health area, sales of Mysimba (weight loss drug) are falling 20%(!) and they are losing over 11 mill kr before tax. This is how I feel almost every single report is, I've owned them for some years now. It has been a terrible investment.
- ·29.1.Norne Sec. reiterates target price NOK36 ahead of the Q4 report: Material revenue gains, albeit higher amortisation expectations in 4Q Navamedic’s 4Q figures are expected to reflect a more comprehensive contribution from the consolidation of dne. Solid underlying growth across all segments and continued strategic execution observed thus far reinforce our positive view on the stock. While higher amortisation of intangibles is likely to weigh on near-term reported earnings, we expect margins to benefit from the higher-margin dne portfolio and Flexilev. We reiterate our BUY recommendation and maintain our TP at NOK 36/sh., underpinned by confidence in the company’s long-term growth and value-creation potential. With offsetting developments, EPS is estimated to stay negative Navamedic will report 4Q results on February 12th. We estimate 4Q revenues at NOK 163.7m, implying an increase of ~25% YoY and ~18% QoQ. The topline is expected to reflect acquisition-driven growth gains in the quarter. We also expect the company to incur transaction-related costs of ~NOK 1.6m (vs NOK 2.3m in 3Q). For 4Q, we forecast adj. EBITDA of NOK 15.6m. Amortisation expenses are projected to increase in 4Q and remain elevated thereafter, driven by a larger intangible base following the dne acquisition, as well as the commencement of amortisation for parts of the Flexilev intangibles from 4Q25. We forecast EPS of NOK -0.10, or NOK -0.04 on an adjusted basis
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
0
Myynti
Määrä
4 650
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt